5.80
+0.22(+3.94%)
Currency In USD
| Previous Close | 5.58 |
| Open | 5.61 |
| Day High | 5.92 |
| Day Low | 5.6 |
| 52-Week High | 21.79 |
| 52-Week Low | 4.93 |
| Volume | 297,025 |
| Average Volume | 264,726 |
| Market Cap | 220.62M |
| PE | -2.86 |
| EPS | -2.03 |
| Moving Average 50 Days | 5.61 |
| Moving Average 200 Days | 9.5 |
| Change | 0.22 |
If you invested $1000 in Entrada Therapeutics, Inc. (TRDA) since IPO date, it would be worth $242.17 as of September 29, 2025 at a share price of $5.8. Whereas If you bought $1000 worth of Entrada Therapeutics, Inc. (TRDA) shares 3 years ago, it would be worth $373.23 as of September 29, 2025 at a share price of $5.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
GlobeNewswire Inc.
Sep 05, 2025 11:00 AM GMT
-- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- -- Announced in advance of World Duchenne Awareness
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
Maha Radhakrishnan, MD Maha Radhakrishnan, MD BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. “We are pleased to have Dr
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jun 02, 2025 8:30 PM GMT
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units (“RSUs”) to six newly-hired non-executive employees under the Company’s 2025